Related Experiment Video
Updated: Dec 4, 2025
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Review of inflammatory bowel disease and COVID-19
Keith Sultan1, Anjali Mone2, Laura Durbin3
1Division of Gastroenterology, Northwell Health, North Shore University Hospital and Long Island Jewish Medical Center, Great Neck, NY 10021, United States.
Insights
Inflammatory Bowel Disease (IBD) patients face increased risks from COVID-19 due to immune-compromising therapies. This review summarizes current data on COVID-19 outcomes and management strategies for IBD patients.
Area of Science:
- Gastroenterology
- Immunology
- Infectious Diseases
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, poses significant risks, especially to individuals with compromised immune systems.
- Inflammatory Bowel Disease (IBD) involves immune dysregulation, and its treatments often involve immunosuppression.
- Gastroenterologists worldwide are concerned about COVID-19 outcomes and management for IBD patients.
Purpose of the Study:
- To review the latest clinical observations and outcomes of the Inflammatory Bowel Disease population regarding COVID-19.
- To provide a concise summary of current expert perspectives on managing IBD during the COVID-19 pandemic.
Main Methods:
- Literature review of recent clinical data and expert opinions.
- Synthesis of information on COVID-19 impact on IBD patients.
- Analysis of current IBD management strategies in the context of the pandemic.
Main Results:
- Early reports indicate higher morbidity and mortality in elderly and comorbid populations with COVID-19.
- IBD patients on immunosuppressive therapies may be at heightened risk for severe COVID-19 outcomes.
- Accumulating data guides evolving management strategies for IBD during the pandemic.
Conclusions:
- The intersection of IBD and COVID-19 necessitates careful consideration of patient risk and treatment.
- Updated management guidelines are crucial for optimizing care for IBD patients during the pandemic.
- Ongoing research is vital to fully understand and mitigate COVID-19 risks in the IBD population.
Abstract:
The first cases of a novel corona virus infection were reported in Wuhan China in December of 2019, followed by the declaration of an international pandemic by the World Health Organization in March 2020. Early reports of the virus, now known as severe acute respiratory syndrome coronavirus 2, and its clinical disease coronavirus disease 2019 (COVID-19), has shown higher rates of morbidity and mortality in the elderly and those with pre-existing medical conditions. Of particular concern is the safety of those with compromised immune systems. Inflammatory Bowel disease (IBD) is itself caused by a disordered immune response, with the most effective medical therapies being immune suppressing or modifying. As such, the risk of COVID-19, virus related outcomes, and appropriate management of IBD patients during the global pandemic is of immediate concern to gastroenterologists worldwide. There has been a rapid accumulation of clinical data and expert opinion on the topic. This review will highlight the latest source information on clinical observation/outcomes of the IBD population and provide a concise summary of the most up to date perspectives on IBD management in the age of COVID-19.
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: